HSCS Stock Overview
A medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HeartSciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.99 |
| 52 Week High | US$52.00 |
| 52 Week Low | US$2.36 |
| Beta | 3.19 |
| 11 Month Change | -42.39% |
| 3 Month Change | -22.34% |
| 1 Year Change | -88.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.24% |
Recent News & Updates
Shareholder Returns
| HSCS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -13.6% | -1.2% | -0.09% |
| 1Y | -88.0% | 30.2% | 38.6% |
Return vs Industry: HSCS underperformed the US Medical Equipment industry which returned 32.5% over the past year.
Return vs Market: HSCS underperformed the US Market which returned 39.5% over the past year.
Price Volatility
| HSCS volatility | |
|---|---|
| HSCS Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HSCS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HSCS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Andrew Simpson | heartsciences.com |
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024.
HeartSciences Inc. Fundamentals Summary
| HSCS fundamental statistics | |
|---|---|
| Market cap | US$2.79m |
| Earnings (TTM) | -US$7.29m |
| Revenue (TTM) | US$18.60k |
146.8x
P/S Ratio-0.4x
P/E RatioIs HSCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSCS income statement (TTM) | |
|---|---|
| Revenue | US$18.60k |
| Cost of Revenue | US$6.08k |
| Gross Profit | US$12.52k |
| Other Expenses | US$7.30m |
| Earnings | -US$7.29m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.98 |
| Gross Margin | 67.31% |
| Net Profit Margin | -39,193.77% |
| Debt/Equity Ratio | 8.4% |
How did HSCS perform over the long term?
See historical performance and comparison